GlassScriptPhysician profile
Marc A Edelstein
NPI 1669488821
$5,498.56
in general payments reported to CMS, 2019-2025
26 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $225 · 2021: $546 · 2022: $655 · 2023: $1,051 · 2024: $1,392 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,231 · Education: $46.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,231.12 |
| Education | $46.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,871.06 | 2019-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $650.87 | 2019-2025 | Entyvio |
| Abbvie INC. | $432.56 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.61 | 2019-2025 | Trulance, Xifaxan |
| Qol Medical, LLC | $400.09 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $240.48 | 2022-2025 | Dupixent |
| Allergan, INC. | $199.10 | 2019 | |
| Exact Sciences Corporation | $187.00 | 2023-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $173.58 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $139.61 | 2019-2023 | Rebyota |
| Intuitive Surgical, INC. | $132.34 | 2022 | |
| Boston Scientific Corporation | $130.02 | 2019 | |
| Janssen Biotech, INC. | $108.33 | 2019-2022 | |
| Capsovision, INC. | $65.24 | 2023-2025 | Capsocam Plus |
| Phathom Pharmaceuticals, INC. | $63.26 | 2024-2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.74 | 2021 | |
| Pfizer INC. | $36.99 | 2019-2020 | |
| Novo Nordisk INC | $33.47 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $28.33 | 2022 | |
| Shield Therapeutics INC | $25.44 | 2023 | Accrufer |
| Endo Pharmaceuticals INC. | $25.00 | 2019 | |
| Albireo Pharma, INC. | $23.67 | 2023 | Bylvay |
| Mirum Pharmaceuticals, INC. | $20.91 | 2023 | Livmarli |
| Ironwood Pharmaceuticals, INC | $17.82 | 2024 | |
| Celgene Corporation | $13.60 | 2021 | |
| Romark Laboratories, Lc | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Edelstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.